|Videos|December 22, 2022
Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy
Author(s)Karim Chamie, MD
Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.
Advertisement
Advertisement
Related to this article
The approval is supported by data from the phase 3 VOLGA trial.
enGene expects to initiate a BLA submission by the end of 2026.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5